Vertex explodes higher on drug data
Jon "DRJ" Najarian | firstname.lastname@example.org
Vertex Pharmaceuticals said its VX-661 compound improved breathing for patients suffering from cystic fibrosis. The Phase II study combined the drug with another one of the company's products that is already in the market. VRTX rockets 61 percent before the bell on my tradeMONSTER platform.
Dell Lower as Blackstone Backs Out
Dell had surged on takeover chatter, but now Blackstone Group is backing out. The private-equity firm cited the recent plunge in PC sales as the reason. DELL falls almost 3 percent in early trading.
Air Methods Expects Surprise Loss
Air Methods said it expects to report a first-quarter loss of $0.14 to $0.16 a share. Analysts, however, had expected profit of $0.32 a share from the medical-transport company. AIRM drops 17 percent in the premarket.